Last reviewed · How we verify
NCT03812939
Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
trial testing Octreotide in Gastric NET in 30 participants. Status unknown.
31 December 2019
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 January 2019 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Octreotide (OCTREOTIDE) — full drug profile →
Conditions studied
- Gastric NET — all drugs for Gastric NET →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 80, any sex, with Gastric NET. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the efficacy of Long-acting Somastostatin analogs as treatment for type I gastric neuroendocrine tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.
Colao A, de Nigris F, Modica R, Napoli C. · · 2020 · cited 31× · PMID 33384663 · DOI 10.3389/fendo.2020.604341
Verify or expand the search:
- PubMed search for NCT03812939
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Octreotide
Trials testing the same drug.
- NCT06865677 — Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas · Phase 2 · terminated
- NCT06085976 — Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, · Phase 2 · unknown
- NCT04048707 — Angiotensin 2 for Hepatorenal Syndrome · Phase 2 · withdrawn
- NCT04028323 — Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Varice · Phase 4 · unknown
- NCT04027348 — Palliative Management of Inoperable Malignant Bowel Obstruction · Phase 2 · terminated
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03812939 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 23 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03812939.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing